Thus, our findings suggest that Egr-1 is a crucial proangiogenic transcription factor triggered by cancer-derived EVs and that ERK1/2 and JNK are upstream signaling pathways involved in EV-mediated endothelial Egr-1 activation. Here, EGR1 is linked to cancer.